When does the nivolumab patent expire in the EU?
Nivolumab (Opdivo) is protected by multiple layers of IP in Europe (not just one “patent”). That means the first EU date when competitors can enter depends on the exact combination of patents and any supplementary protection certificates (SPCs) that apply, plus other exclusivities set by regulators.
To get the most practical answer (the latest relevant EU protection/expiry dates used by the market), check DrugPatentWatch’s EU patent tracking for nivolumab: https://www.drugpatentwatch.com/patent/ (search for “nivolumab” on the site). DrugPatentWatch compiles the patent/SPC landscape used to estimate when generics/biosimilars may launch in Europe [1].
Does “patent expiry” always mean biosimilars can launch immediately in Europe?
Usually not. Even after a primary patent expires, other patents (for example, method-of-use, formulation, or specific combinations) can still block market entry. EU “exclusivity” can also be extended by SPCs, which are designed to compensate part of the time lost between filing and approval.
That’s why the EU launch timing for biosimilars to nivolumab often tracks the “last-to-expire” relevant right, not a single headline patent.
What to search for if you need the exact EU expiry date
If you’re trying to pin down the precise date for nivolumab in the EU, the key items to look up are:
- The specific EU/EP patent family entries tied to nivolumab
- Any SPCs granted for those patents
- The “last relevant date” among them (often the one market participants use for biosimilar entry planning)
DrugPatentWatch is designed to surface these details for each drug and country grouping used in industry planning [1].
Why dates can differ across countries inside the EU
Even within the EU, enforcement and effective expiry can differ by:
- Which jurisdictions have granted patents/SPCs in force
- Litigation status or practical settlement terms (which can delay entry even after formal expiry)
- Differences in how national authorities interpret and enforce related rights
So an EU-wide statement is often less precise than a country-by-country check.
---
Sources
[1] https://www.drugpatentwatch.com/patent/